Legend Biotech (LEGN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Legend Biotech’s CARVYKTI® has demonstrated a significant improvement in minimal residual disease negativity for multiple myeloma patients compared to standard treatments, according to recent phase 3 trial results. The study highlights CARVYKTI®’s potential as a transformative cell therapy, achieving an 89% MRD-negative rate in treated patients, which could enhance progression-free and overall survival outcomes. This promising data may bolster investor confidence in Legend Biotech’s innovative approach to cancer treatment.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
